PharmX Technologies (PHX) H1 2026 earnings summary

Executive summary

• Achieved 3% year-over-year revenue growth to AUD 3.9 million for H1 FY26, with strong performance across core business lines and positive EBITDA despite increased investment in growth initiatives; net loss after tax of $512,000 compared to a prior year profit, driven by higher development and marketing costs.

• Launched new single platform Marketplace in November 2025, driving record Marketplace GCV and rapid pharmacy adoption, with over 1,200 pharmacies live and 39% month-on-month growth in StockView usage.

• Secured a multi-year strategic partnership with Sigma Chemist Warehouse, including a 10% equity stake, board representation, and a pathway to increase to 19.9%, positioning the company as a key technology and growth partner in ANZ.

• Expanded New Zealand operations, with NZ revenues up 54% year-over-year.

Financial highlights

• Revenue up 3% year-over-year to AUD 3.9 million; Marketplace revenue up 24%, Gateway revenue up 5%.

• EBITDA positive at AUD 0.5 million, down from AUD 1.1 million prior period due to growth investments; net loss after tax of $0.5 million compared to a $0.2 million profit in H1 FY25.

• Operating costs rose to AUD 3.4 million, up AUD 0.7 million, driven by investment in development, sales, marketing, and IT; personnel and technology costs up 36%.

• Strong cash position at AUD 3.2 million as of December 31, 2025.

• Capital expenditure on product development was AUD 1 million, up from AUD 654,000.

Outlook and guidance

• Expect integration fees and marketing partnership revenues to resume in H2 as new platform matures; continued investment in technology and product development planned.

• Strategic alliance with Sigma expected to accelerate New Zealand expansion, Single Platform strategy, and open international growth opportunities.

• Focus on expanding supplier network, increasing pharmacy engagement, and growing transaction volumes and analytics capabilities.